

Citations

1. Badawy AA, Evans M. The role of free serum tryptophan in the biphasic effect of acute ethanol administration on the concentrations of rat brain tryptophan, 5-hydroxytryptamine and 5-hydroxyindol-3-ylacetic acid. *Biochem J* 1976;160:315-324.
2. Pinelli A, Trivulzio S, Malvezzi L, Zecca L. Potentiation of the analgesic effects of tryptophan by allopurinol in rats. *Arzneimittelforschung* 1991;41:809-811.
3. Daya S, Nonaka KO, Buzzell GR, Reiter RJ. Heme precursor 5-aminolevulinic acid alters brain tryptophan and serotonin levels without changing pineal serotonin and melatonin concentrations. *J Neurosci Res* 1989;23:304-309.
4. Becking GC, Johnson WJ. The inhibition of tryptophan pyrrolase by allopurinol, an inhibitor of xanthine oxidase. *Can J Biochem* 1967;45:1667-1672.
5. Haskovec L, Dostal T, Jirak R. The action of allopurinol as an inhibitor of liver tryptophan pyrrolase in depressions. *Act Nerv Super (Praha)* 1972;14:131-132.
6. Green AR, Aronson JK, Curzon G, Woods HF. Metabolism of an oral tryptophan load. II. Effect of pretreatment with the putative tryptophan pyrrolase inhibitors nicotinamide or allopurinol. *Br J Clin Pharmacol* 1980;10:611-615.
7. Stern SL, Mendels J. Drug combinations in the treatment of refractory depression: a review. *J Clin Psychiatry* 1981;42:368-373.
8. Coassolo P, Briand C, Bourdeaux M, Sari JC. Microcalorimetric method to determine competitive binding: action of a psychotropic drug (dipotassium chlorazepate) on l-tryptophan-human serum albumin complex. *Biochim Biophys Acta* 1978;538:512-520.
9. Walinder J, Carlsson A, Persson R. 5-HT reuptake inhibitors plus tryptophan in endogenous depression. *Acta Psychiatr Scand Suppl* 1981;290:179-190.
10. Barr LC, Heninger GR, Goodman W et al. Effects of fluoxetine administration on mood response to tryptophan depletion in healthy subjects. *Biol Psychiatry* 1997;41:949-954.
11. Delgado PL, Miller HL, Salomon RM et al. Tryptophan-depletion challenge in depressed patients treated with desipramine or fluoxetine: implications for the role of serotonin in the mechanism of antidepressant action. *Biol Psychiatry* 1999;46:212-220.
12. Porter RJ, Mulder RT, Joyce PR. Baseline prolactin and l-tryptophan availability predict response to antidepressant treatment in major depression. *Psychopharmacology (Berl)* 2003;165:216-221.
13. Meltzer H, Bastani B, Jayathilake K, Maes M. Fluoxetine, but not tricyclic antidepressants, potentiates the 5-hydroxytryptophan-mediated increase in plasma cortisol and prolactin secretion in subjects with major depression or with obsessive compulsive disorder. *Neuropsychopharmacology* 1997;17:1-11.
14. Levitan RD, Shen JH, Jindal R et al. Preliminary randomized double-blind placebo-controlled trial of tryptophan combined with fluoxetine to treat major depressive disorder: antidepressant and hypnotic effects. *J Psychiatry Neurosci* 2000;25:337-346.
15. Mitchell PB. Drug interactions of clinical significance with selective serotonin reuptake inhibitors. *Drug Saf* 1997;17:390-406.
16. Central nervous system drugs, antidepressants, selective serotonin reuptake inhibitors. In: Threlkeld DS, ed. *Facts and Comparisons Drug Information*. St Louis: Facts and Comparisons; April 1997.
17. Van der Mast RC, Fekkes D. Serotonin and amino acids: partners in delirium pathophysiology? *Semin Clin Neuropsychiatry* 2000;5:125-131.
18. Steiner W, Fontaine R. Toxic reaction following the combined administration of fluoxetine and l-tryptophan: five case reports. *Biol Psychiatry* 1986;21:1067-1071.
19. Carroll BJ. Prediction of treatment outcome with lithium. *Arch Gen Psychiatry* 1979;36:870-878.
20. Maj M, Pirozzi R, Starace F. Previous pattern of course of the illness as a predictor of response to lithium prophylaxis in bipolar patients. *J Affect Disord* 1989;17:237-241.
21. Rujescu D, Giegling I, Bondy B et al. Association of anger-related traits with SNPs in the TPH gene. *Mol Psychiatry* 2002;7:1023-1029.
22. Kato T, Inubushi T, Kato N. Prediction of lithium response by 31P-MRS in bipolar disorder. *Int J Neuropsychopharmacol* 2000;3:83-85.
23. Serretti A, Lilli R, Smeraldi E. Pharmacogenetics in affective disorders. *Eur J Pharmacol* 2002;438:117-128.
24. Serretti A, Artioli P. Predicting response to lithium in mood disorders: role of genetic polymorphisms. *Am J Pharmacogenomics* 2003;3:17-30.
25. Chotai J, Serretti A, Lattuada E et al. Gene-environment interaction in psychiatric disorders as indicated by season of birth variations in tryptophan hydroxylase (TPH), serotonin transporter (5-HTTLPR) and dopamine receptor (DRD4) gene polymorphisms. *Psychiatry Res* 2003;119:99-111.
26. Serretti A, Lilli R, Lorenzi C et al. Tryptophan hydroxylase gene and response to lithium prophylaxis in mood disorders. *J Psychiatr Res* 1999;33:371-377.
27. Serretti A. Lithium long-term treatment in mood disorders: clinical and genetic predictors. *Pharmacogenomics* 2002;3:117-129.

Citations and Reference Literature: Tryptophan

28. Brewerton TD, Reus VI. Lithium carbonate and l-tryptophan in the treatment of bipolar and schizoaffective disorders. *Am J Psychiatry* 1983;140:757-760.
29. Levy AB, Bucher P, Votolato N. Myoclonus, hyperreflexia and diaphoresis in patients on phenelzine-tryptophan combination treatment. *Can J Psychiatry* 1985;30:434-436.
30. Thomas JM, Rubin EH. Case report of a toxic reaction from a combination of tryptophan and phenelzine. *Am J Psychiatry* 1984;141:281-283.
31. Pope HG, Jr., Jonas JM, Hudson JI, Kafka MP. Toxic reactions to the combination of monoamine oxidase inhibitors and tryptophan. *Am J Psychiatry* 1985;142:491-492.
32. Goff DC. Two cases of hypomania following the addition of l-tryptophan to a monoamine oxidase inhibitor. *Am J Psychiatry* 1985;142:1487-1488.
33. Alvine G, Black DW, Tsuang D. Case of delirium secondary to phenelzine/l-tryptophan combination. *J Clin Psychiatry* 1990;51:311.
34. Sifton DW et al. Physicians' Desk Reference. Montvale, NJ: Medical Economics Company; 2000:1509-1513.
35. Product Information: Meridia. Mount Olive, NJ: Knoll Pharmaceutical Company; 1999.
36. Chouinard G, Young SN, Annable L, Sourkes TL. Tryptophan-nicotinamide, imipramine and their combination in depression: a controlled study. *Acta Psychiatr Scand* 1979;59:395-414.
37. Shaw DM, Macsweeney DA, Hewland R, Johnson AL. Tricyclic antidepressants and tryptophan in unipolar depression. *Psychol Med* 1975;5:276-278.
38. Walinder J, Skott A, Carlsson A et al. Potentiation of the antidepressant action of clomipramine by tryptophan. *Arch Gen Psychiatry* 1976;33:1384-1389.

Reference Literature

- [No authors listed.] Lithium increases serotonin release and decreases metabolism: implications for theories of schizophrenia. *Science* 1979;205(9).
- [No authors listed.] Product information: Alti-Tryptophan, L-tryptophan. Mississauga, Ontario: AltiMed Pharmaceutical Company; 1999.
- Adachi J, Ueno Y, Tatsuno Y, et al. A comparative study of tissue distribution and excretion among three substances implicated in eosinophilia-myalgia syndrome. *Adv Exp Med Biol* 1996;398:365-370.
- Adachi J, Gomez M, Smith CC, et al. Accumulation of 3-(phenylamino)alanine, a constituent in L-tryptophan products implicated in eosinophilia-myalgia syndrome, in blood and organs of the Lewis rats. *Arch Toxicol* 1995;69(4):266-270.
- Agarwal DP, Ziemsen B, Goedde HW, et al. Free and bound plasma tryptophan levels in psychiatric disorders. In: Schlossberger HG, Kochen W, Linzen B, et al, eds. *Progress in tryptophan and serotonin research*. Berlin: Walter de Gruyter; 1984:391-396.
- Allegri G, Angi MR, Costa C, et al. Tryptophan and kynurenine in senile cataract. In: Schlossberger HG, Kochen W, Linzen B, et al, eds. *Progress in tryptophan and serotonin research*. Berlin: Walter de Gruyter; 1984:469-472.
- Bell C, Forshall S, Adrover M, et al. Does 5-HT restrain panic? A tryptophan depletion study in panic disorder patients recovered on paroxetine. *J Psychopharmacol* 2002;16(1):5-14.
- Belongia EA, Hedberg CW, Gleich GJ, et al. An investigation of the cause of the eosinophilia-myalgia syndrome associated with tryptophan use. *N Engl J Med* 1990;323:357-365.
- Brenneman DE, Page SW, Schultzberg M, et al. A decomposition product of a contaminant implicated in L-tryptophan eosinophilia myalgia syndrome affects spinal cord neuronal cell death and survival through stereospecific, maturation and partly interleukin-1-dependent mechanisms. *J Pharmacol Exp Ther* 1993;266(2):1029-1035.
- Bunce GE, Hess, JL, Davis D. Cataract formation following limited amino acid intake during gestation and lactation. *Soc Exp Biol Med* 1984;176:485-489.
- Calandra C, Zappala E, Bonomo V, et al. [5-hydroxytryptophan in combination with allopurinol in depressions.] *Minerva Psichiatr* 1981;22(3):131-135. [Italian]
- Castot A, Bidault I, Bournierias I, et al. ["Eosinophilia-myalgia" syndrome due to L-tryptophan containing products: cooperative evaluation of French Regional Centers of Pharmacovigilance: analysis of 24 cases.] *Therapie* 1991;46(5):355-365. [French]
- Chan BS, Gaudins A, Whyte IM, et al. Serotonin syndrome resulting from drug interactions. *Med J Aust* 1998;169(10):523-525.
- Chotai J, Serretti A, Lattuada E, et al. Gene-environment interaction in psychiatric disorders as indicated by season of birth variations in tryptophan hydroxylase (TPH), serotonin transporter (5-HTTLPR) and dopamine receptor (DRD4) gene polymorphisms. *Psychiatry Res* 2003;119(1-2):99-111.
- Coplan JD, Gorman JM. Detectable levels of fluoxetine metabolites after discontinuation: an unexpected serotonin syndrome. *Am J Psychiatry* 1993;150:837.

Citations and Reference Literature: Tryptophan

- Deloukas P, Bentley D. The HapMap project and its application to genetic studies of drug response. *Pharmacogenomics J* 2004;4(2): 88-90.
- den Boer JA, Westenberg HG. Behavioral, neuroendocrine, and biochemical effects of 5-hydroxytryptophan administration in panic disorder. *Psychiatry Res* 1990;31(3):267-278.
- Fernstrom JD, Wurtman RJ. Brain serotonin content physiological dependence on plasma tryptophan levels. *Science* 1971;173:149-151.
- Figueras G, Perez V, San Martino O, et al. Pretreatment platelet 5-HT concentration predicts the short-term response to paroxetine in major depression: Grupo de Trastornos Afecivos. *Biol Psychiatry* 1999;46(4):518-524.
- Fuller RW. Biochemical pharmacology of the serotonin system. *Adv Neurol* 1986;43:469-480. (Review)
- Gillman PK, Bartlett JR, Bridges PK, et al. Relationships between tryptophan concentrations in human plasma, cerebrospinal fluid and cerebral cortex following tryptophan infusion. *Neuropharmacology* 1980;19:1241-1242.
- Green AR, Aronson JK. Metabolism of an oral tryptophan load III: effect of a pyridoxine supplement. *Br J Clin Pharmacol* 1980;10(6): 617-619.
- Green AR, Aronson JK, Cowen PJ. The pharmacokinetics of L-tryptophan following its intravenous and oral administration. *Br J Clin Pharmacol* 1985;20(4):317-321.
- Green AR, Aronson JK, Curzon G, et al. Metabolism of an oral tryptophan load: I: effects of dose and pretreatment with tryptophan. *Br J Clin Pharmacol* 1980;10(6):603-610.
- Green AR, Bloomfield MR, Woods HF, et al. Metabolism of an oral tryptophan load by women and evidence against the induction of tryptophan pyrrolase by oral contraceptives. *Br J Clin Pharmacol* 1978;5(3):233-241.
- Ito J, Hosaki Y, Torigoe Y, et al. Identification of substances formed by decomposition of peak E substance in tryptophan. *Food Chem Toxicol* 1992;30(1):71-81.
- Jiang, GC-T, Yohrling GJ IV, Schmitt JD, et al. Identification of substrate orienting and phosphorylation sites within tryptophan hydroxylase using homology-based molecular modeling. *J Mol Biol* 2000;302(4):1005-1017.
- Johnson L, El-Khoury A, Aberg-Wistedt A, et al. Tryptophan depletion in lithium-stabilized patients with affective disorder. *Int J Neuropsychopharmacol* 2001;4(4):329-336.
- Kamb ML, Murphy JJ, Jones JL, et al. Eosinophilia-myalgia syndrome in L-tryptophan-exposed patients. *JAMA* 1992;267(1):77-82.
- Kim SW, Park SY, Hwang O. Up-regulation of tryptophan hydroxylase expression and serotonin synthesis by sertraline. *Mol Pharmacol* 2002;61(4):778-785.
- Kimball RW, Friedman AP, Vallejo E. Effect of serotonin in migraine patients. *Neurology* 1960;10:107-111.
- Lehmann J, Persson S, Walinder J, et al. Tryptophan malabsorption in dementia: improvement in certain cases after tryptophan therapy as indicated by mental behavior and blood analysis. *Acta Psychiatr Scand* 1981;64:123-131.
- Lee NS, Muhs G, Wagner GC, et al. Dietary pyridoxine interaction with tryptophan or histidine on brain serotonin and histamine metabolism. *Pharmacol Biochem Behav* 1988;29(3):559-564.
- Livingston MG, Livingston HM. Monoamine oxidase inhibitors: an update on drug interactions. *Drug Saf* 1996;14(4):219-227. (Review)
- Loew D. [L-Tryptophan: an essential amino acid for structural and functional metabolism.] *Fortschr Med* 1997;115:40-42. [German]
- Lucini V, Lucca A, Catalano M, et al. Predictive value of tryptophan/large neutral amino acids ratio to antidepressant response. *J Affect Disord* 1996;36(3-4):129-133.
- Marley E, Wozniak KM. Interactions of non-selective monoamine oxidase inhibitors, tranylcypromine and nialamide, with inhibitors of 5-hydroxytryptamine, dopamine or noradrenaline re-uptake. *J Psychiatr Res* 1984;18(2):191-203.
- Martin RW, Duffy J, Engel AG, et al. The clinical spectrum of the eosinophilia-myalgia syndrome associated with L-tryptophan ingestion: clinical features in 20 patients and aspects of pathophysiology. *Ann Intern Med* 1990;113:124-134.
- Martin TG. Serotonin syndrome. *Ann Emerg Med* 1996;28(5):520-526. (Review)
- Mauri MC, Boscati L, Volonteri LS, et al. Predictive value of amino acids in the treatment of major depression with fluvoxamine. *Neuropsychobiology* 2001;44(3):134-138.
- Messiha FS. Fluoxetine: adverse effects and drug-drug interactions. *J Toxicol Clin Toxicol* 1993;31(4):603-630.
- Meyer JS, Welch KM, Deshmukh VD, et al. Neurotransmitter precursor amino acids in the treatment of multi-infarct dementia and Alzheimer's disease. *J Am Geriatr Soc* 1977;25(7):289-298.
- Mitchell PB. Drug interactions of clinical significance with selective serotonin reuptake inhibitors. *Drug Saf* 1997;17(6):390-406. (Review)
- Modlinger RS, Schonmuller JM, Arora SP. Stimulation of adolesterone, renin, and cortisol by tryptophan. *J Clin Endocrin Metab* 1979;48(4):599-603.
- Moller SE. 5-HT uptake inhibitors and tricyclic antidepressants: relation between tryptophan availability and clinical response in depressed patients. *Eur Neuropsychopharmacol* 1990;1(1):41-44.

Citations and Reference Literature: Tryptophan

- Moller SE, Amdisen A. Plasma neutral amino acids in mania and depression: variation during acute and prolonged treatment with L-tryptophan. *Biol Psychiatr* 1979;14(1):131-139.
- Moreno FA, Heninger GR, McGahuey CA, et al. Tryptophan depletion and risk of depression relapse: a prospective study of tryptophan depletion as a potential predictor of depressive episodes. *Biol Psychiatry* 2000;48(4):327-329.
- Moskowitz DS, Pinard G, Zuroff DC, et al. The effect of tryptophan on social interaction in everyday life: a placebo-controlled study. *Neuropsychopharmacology* 2001;25(2):277-289.
- Nedopil N, Einhaupl K, Ruther E, et al. L-tryptophan in chronic insomnia. In: Schlossberger HG, Kochen W, Linzen B, et al, eds. *Progress in tryptophan and serotonin research*. Berlin: Walter de Gruyter; 1984;305-309.
- Neumeister A, Konstantinidis A, Stastny J, et al. Association between serotonin transporter gene promoter polymorphism (5HTTLPR) and behavioral responses to tryptophan depletion in healthy women with and without family history of depression. *Arch Gen Psych* 2002;59(7):613-620.
- Nielson HK, Hurrell RF. Content and stability of tryptophan in foods. In: Schlossberger HG, Kochen W, Linzen B, et al, eds. *Progress in tryptophan and serotonin research*. Berlin: Walter de Gruyter; 1984;527-534.
- Niskamen P, Huttunen M, Tamminen T, et al. The daily rhythm of plasma tryptophan and tyrosine in depression. *Br J Psychiatr* 1976;128:67-73.
- Oates JA, Sjoerdsma A. Neurologic effects of tryptophan in patients receiving a monoamine oxidase inhibitor. *Neurology* 1960;10:1076-1078.
- Ooi TK. The serotonin syndrome. *Anaesthesia* 1991;46:507-508.
- Pellegrino TC, Bayer BM. Specific serotonin reuptake inhibitor-induced decreases in lymphocyte activity require endogenous serotonin release. *Neuroimmunomodulation* 2000;8(4):179-187.
- Perez V, Bel N, Celada P, et al. Relationship between blood serotonergic variables, melancholic traits, and response to antidepressant treatments. *J Clin Psychopharmacol* 1998;18(3):222-230.
- Peters EJ, Slager SL, McGrath PJ, et al. Investigation of serotonin-related genes in antidepressant response. *Mol Psychiatry* 2004;9(9):879-889.
- Poldinger W, Calanchini B, Schwarz W. A functional-dimensional approach to depression: serotonin deficiency as a target syndrome in a comparison of 5-hydroxytryptophan and fluvoxamine. *Psychopathology* 1991;24(2):53-81.
- Radomski JW, Dursun SM, Reveley MA, et al. An exploratory approach to the serotonin syndrome: an update of clinical phenomenology and revised diagnostic criteria. *Med Hypotheses* 2000;55(3):218-224.
- Rujescu D, Giegling I, Bondy B, et al. Association of anger-related traits with SNPs in the TPH gene. *Mol Psychiatry* 2002;7(9):1023-1029.
- Quintana J. Platelet serotonin and plasma tryptophan decreases in endogenous depression: clinical, therapeutic, and biological correlations. *J Affect Disord* 1992;24(2):55-62.
- Schneider-Helmert D, Spinweber CL. Evaluation of L-tryptophan for treatment of insomnia: a review. *Psychopharmacology (Berl)* 1986;89(1):1-7. (Review)
- Serretti A, Lilli R, Smeraldi E. Pharmacogenetics in affective disorders. *Eur J Pharmacol* 2002;438(3):117-128. (Review)
- Serretti A, Zanardi R, Cusin C, et al. Tryptophan hydroxylase gene associated with paroxetine antidepressant activity. *Eur Neuropsychopharmacol* 2001;11(5):375-380.
- Shaw DM. Tricyclic antidepressants, tryptophan and affective disorder. *Postgrad Med J* 1976;52(3 Suppl):47-51.
- Shaw DM, Johnson AL, MacSweeney DA. Tricyclic antidepressants and tryptophan in unipolar affective disorder. *Lancet* 1972;2(7789):1245.
- Shimeno H, Fukumoto Y, Fuji M, et al. Effect of combined administration of tryptophan with putative tryptophan pyrrolase inhibitors, DL-3-pyridylalanine, allopurinol or nicotinamide, on brain serotonin concentration. *Chem Pharm Bull (Tokyo)* 1984;32(6):2353-2363.
- Smith KA, Fairburn CG, Cowen PJ. Symptomatic relapse in bulimia nervosa following acute tryptophan depletion. *Arch Gen Psychiatry* 1999;56(2):171-176.
- Spillmann MK, Van der Does AJ, Rankin MA, et al. Tryptophan depletion in SSRI-recovered depressed outpatients. *Psychopharmacology (Berl)* 2001;155(2):123-127.
- Steiner W, Fontaine R. Toxic reaction following the combined administration of fluoxetine and tryptophan: five case reports. *Biol Psychiatry* 1986;21:1067-1071.
- Sternbach H. The serotonin syndrome. *Am J Psychiatry* 1991;148(6):705-713. (Review)
- Sternberg EM. Pathogenesis of L-tryptophan eosinophilia myalgia syndrome. *Adv Exp Med Biol* 1996;398:325-330.

Citations and Reference Literature: Tryptophan

- Sternberg EM, Van Woert MH, Young SN, et al. Development of a scleroderma-like illness during therapy with L-5-hydroxytryptophan and carbidopa. *N Engl J Med* 1980;303(14):782-787.
- Toyo'oka T, Yamazaki T, Tanimoto T, et al. Characterization of contaminants in EMS-associated L-tryptophan samples by high-performance liquid chromatography. *Chem Pharm Bull (Tokyo)* 1991;39(3):820-822.
- Trucksess MW. Separation and isolation of trace impurities in L-tryptophan by high-performance liquid chromatography. *J Chromatogr* 1993;630(1-2):147-150.
- Trucksess MW, Thomas FS, Page SW. High-performance liquid chromatographic determination of 1,1'-ethylidenebis(L-tryptophan) in L-tryptophan preparations. *J Pharm Sci* 1994;83(5):720-722.
- van der Mast RC, Fekkes D. Serotonin and amino acids: partners in delirium pathophysiology? *Semin Clin Neuropsychiatry* 2000;5(2):125-131. (Review)
- van Praag HM. Precursors of serotonin, dopamine, and norepinephrine in the treatment of depression. *Adv Biol Psychiatry* 1984;14:54-68.
- van Praag HM, Lemus C. Monoamine precursors in the treatment of psychiatric disorders. In: Wurtman RJ, Wurtman JJ, eds. *Nutrition and the brain*. Vol. 7. New York: Raven Press; 1986. (Review)
- Walinder J, Carlsson A, Persson R. 5-HT reuptake inhibitors plus tryptophan in endogenous depression. *Acta Psychiatr Scand Suppl* 1981;290:179-190.
- Werbach MR. *Foundations of nutritional medicine*. Tarzana, CA: Third Line Press; 1997. (Review)
- Williamson BL, Benson LM, Tomlinson AJ, et al. On-line HPLC-tandem mass spectrometry analysis of contaminants of L-tryptophan associated with the onset of the eosinophilia-myalgia syndrome. *Toxicol Lett* 1997;92:139-148.
- Wolfe F, Russell IJ, Vipraio G, et al. Serotonin levels, pain threshold, and fibromyalgia symptoms in the general population. *J Rheumatol* 1997;24(3):555-559.
- Wood K, Swade C, Harwood J, et al. Comparison of methods for the determination of total and free tryptophan in plasma. *Clin Chim Acta* 1977;80:229-303.
- Wynn V, Adams PW, Folkard J, et al. Tryptophan, depression and steroidal contraception. *J Steroid Biochem* 1975;6(6):965-970.
- Young AH, Hughes JH, Marsh VR, et al. Acute tryptophan depletion attenuates auditory event related potentials in bipolar disorder: a preliminary study. *J Affect Disord* 2002;69(1-3):83-92.
- Yunus MB, Dailey JW, Aldag JC, et al. Plasma tryptophan and other amino acids in primary fibromyalgia: a controlled study. *J Rheumatol* 1992;19(1):90-94.